



IPM

- **Product Development Partnership**
 - In operation as 501c3 for 4 years
 - Headquarters in Silver Spring, MD
 - IPM Belgium office in Brussels
 - Branch offices in Cape Town SA and Nairobi, Kenya
 - >60 Full-time staff and consultants
 - Raised more than \$200 million from 11 donor countries, 2 Foundations, the European Commission, and others.



IPM Programs

- **Research and Development**
- **Clinical and Site Development**
- **Project Management**
- **External Affairs**
- **Finance and Administration**



IPM Infrastructure

- **Formulation (Particle Sciences)**
- **GMP Manufacturing Phase I/II**
- **Non-Human Primate**
- **Screening (St. Georges Medical School)**



Delivery: GMP Manufacture of Semi-Solid Formulations



IPM Clinical Supply Facility
3894 Courtney St., Suite 160
Bethlehem, PA 18017



Approach to Drug Acquisition from Big Pharma

IPM's basic strategy involves licensing of active compounds from commercial pharmaceutical companies for development as microbicides.

Announced Licenses:

- **Johnson & Johnson (Tibotec)**
- **Merck**
- **Bristol Myers-Squibb**
- **Gilead**



Pipeline Expansion and Classes of Drugs

Class	Develop or Significantly Support	Support
NRTI	PMPA	
NNRTI	Dapivirine (TMC120)	UC 781
R5 Blocker	Merck 167 (+2)	PSC Rantes
Fusion/Entry	BMS 793 Locus (early stage) Imquest/Samjin	C52L
Other	RNAi ~Topical Estrogen	



External microbicide formulation groups

- Intravaginal rings, tablets, gels, films
- Queens University, Belfast, Northern Ireland
- University of Auckland, Auckland, New Zealand
- University of Utah, Salt Lake City, Utah, USA
- Novavax, Malvern, PA, USA
- Warner-Chilcott, Larne, N. Ireland
- University of Pittsburgh (planned)



Clinical Site Development

Stage 1

Stage 2

Stage 3

Non SA:

8 countries

11 sites

SA:

12 sites



IPM Clinical Trials

Study	Study name	Location	Volunteers	Status
IPM001	Dapivirine vaginal ring safety study	Belgium	12	Completed
IPM003	Dapivirine gel safety study	South Africa, Rwanda, Tanzania	112	Completed
IPM004	Dapivirine gel PK study	South Africa	18	Completed
IPM005B	Dapivirine gel expanded safety study	Belgium	36	Completed
IPM007	Seroconverter protocol	Various sites	N/A	Planned, 2008
IPM008	Dapivirine vaginal ring safety study	Belgium	13	Completed
IPM009	Dapivirine efficacy study	Various sites	TBD	Planned, 2008
IPM010	Dapivirine gel male tolerance study	Belgium	36	Planned
IPM011	Vaginal ring acceptability study	Kenya, South Africa, Tanzania	200	Q1, 2007
IPM012	Dapivirine gel PK study	TBD	TBD	Q2, 2007
IPM013	Dapivirine vaginal ring PK study	Belgium	60	Q2, 2007
IPM014	Dapivirine gel safety study	South Africa, TBD	TBD	Q3, 2007
IPM015	Dapivirine vaginal ring safety study	South Africa, Tanzania	280	Q3 2007
IPM016	Small volume applicator PK study	TBD	TBD	Q3, 2007
IPM017	Dapivirine vaginal ring safety study	Belgium	TBD	Q3, 2007
IPM018	Vaginal ring feasibility study	Belgium	24	Q2, 2007